Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · OmniAb, Inc. (OABI)

OmniAb raises 2026 revenue outlook to $35 million to $39 million

Positive Impact 4 of 5 guidance Written later

OmniAb reported third-quarter 2026 revenue of $4.0 million, up from $2.2 million a year earlier, and a net loss of $15.7 million, or $0.12 per share, narrowed from $16.5 million, or $0.14 per share. The company raised its full-year 2026 revenue guidance and its year-end cash outlook, which may matter to shareholders because the figures point to higher revenue and a smaller loss than in the prior-year period.

Key points

  • Q3 2026 revenue was $4.0 million versus $2.2 million in Q3 2025; net loss was $15.7 million, or $0.12 per share, versus $16.5 million, or $0.14 per share.
  • 2026 revenue guidance is now $35 million to $39 million, up from $32 million to $36 million previously.
  • Year-end 2026 cash and cash equivalents outlook is $53 million to $57 million, up from $49 million to $53 million.
  • In Q3 2026, OmniAb entered a collaboration and license agreement with Eli Lilly and Company eligible for up to $370 million in milestone payments, plus royalties.

The filing

CompanyOmniAb, Inc. (OABI)
Form8-K, current report
Filed with the SECOct 30, 2026, 7:42 AM ET
Accession number0001846253-26-000049

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.